ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¿ëµµº°, Á¦Ç°º°, ±â¼úº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2033³â)
Human Papilloma Virus Testing Market Size, Share & Trends Analysis Report By Application (Cervical Cancer Screening, Vaginal Cancer Screening), By Product, By Technology, By End Use, By Region, And Segment Forecasts, 2025 - 2033
»óǰÄÚµå : 1813883
¸®¼­Ä¡»ç : Grand View Research
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 110 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,431,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,848,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,683,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(ÀÚȸ»ç Æ÷ÇÔ)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå ¿ä¾à

ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå ±Ô¸ð´Â 2024³â 17¾ï 6,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2033³â¿¡´Â 56¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025³âºÎÅÍ 2033³â±îÁö CAGR 14.14%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ½ÃÀåÀº ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV)°¡ ÀڱðæºÎ¾ÏÀÇ 95% ÀÌ»óÀ» À¯¹ßÇÏ´Â HPV °ü·Ã ¾ÏÀÇ Áõ°¡·Î ÀÎÇØ Ȱ¼ºÈ­µÇ°í ÀÖ½À´Ï´Ù.

È£ÁÖ¿Í °°Àº ±¹°¡¿¡¼­´Â ´õ ³ôÀº ¹Î°¨µµ¸¦ À§ÇØ ÀڱðæºÎ¾Ï °Ë»ç¸¦ HPV DNA °Ë»ç·Î ´ëüÇϰí ÀÖ½À´Ï´Ù. BD³ª Ȧ·ÎÁ÷°ú °°Àº ¼¿ÇÁ »ùÇøµ ŰƮ´Â ¼­ºñ½º°¡ ÃæºÐÈ÷ Á¦°øµÇÁö ¾Ê´Â Áö¿ª¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ¾ÆÇÁ¸®Ä«¿Í ¾Æ½Ã¾Æ¿¡¼­´Â WHOÀÇ ÅðÄ¡ Àü·«°ú NGO°¡ Áö¿øÇÏ´Â ÇÁ·Î±×·¥ÀÌ º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ºÐÀÚÁø´ÜÀÇ ¹ßÀü, ¹øµéÇü ¿©¼º °Ç°­ ÆÐ³Î, ½ÇÇè½Ç ÀÎÇÁ¶óÀÇ °³¼±À¸·Î Àü ¼¼°èÀûÀ¸·Î °Ë»ç Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ºñ¿ë È¿À²¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀڱðæºÎ¾ÏÀº Àü ¼¼°è ¿©¼º¿¡°Ô 4¹øÂ°·Î ÈçÇÑ ¾ÏÀ̸ç, ¿©¼º ¾Ï °ü·Ã »ç¸Á ¿øÀÎ Áß 2À§¸¦ Â÷ÁöÇÕ´Ï´Ù.

2020³â 11¿ù, ¼¼°èº¸°Ç±â±¸(WHO)´Â 'ÀڱðæºÎ¾Ï ÅðÄ¡¸¦ À§ÇÑ ¼¼°è Àü·«'À» ¹ßÇ¥Çϰí, 2030³â±îÁö '90-70-90' ¸ñÇ¥¸¦ ¼³Á¤Çß´Ù - 15¼¼±îÁö ¿©¾Æ 90%¿¡°Ô ¹é½ÅÀ» Á¢Á¾Çϰí, 35¼¼¿Í 45¼¼ ¿©¼ºÀÇ 70%¸¦ °ËÁøÇϰí, Áúº´ÀÌ È®ÀÎµÈ ¿©¼ºÀÇ 90%¸¦ Ä¡·áÇÕ´Ï´Ù. Ä¡·áÇÕ´Ï´Ù. 2022³â, ±ÇÀå °ËÁø ¼ö°Ë·ü 70% ÀÌ»ó¿¡ µµ´ÞÇÑ ±¹°¡´Â 18%¿¡ ºÒ°úÇϸç, Àü ¼¼°è ¼ö°Ë·üÀº ¾ÆÁ÷ ¾à 20%¿¡ ºÒ°úÇÕ´Ï´Ù. HPV´Â ÀڱðæºÎ¾Ï ȯÀÚÀÇ 99.8%ÀÇ ¿øÀÎÀ̸ç, À¯ÀüÀÚÇü 16°ú 18Çü¸¸ 70%¸¦ Â÷ÁöÇÕ´Ï´Ù. 19°¡Áö °íÀ§Çè À¯ÀüÀÚÇüÀÌ HPV °ü·Ã ¾ÏÀÇ 90%¸¦ Â÷ÁöÇÕ´Ï´Ù. HPV °¨¿°Àº ´ëºÎºÐ ¹«Áõ»óÀ̱⠶§¹®¿¡ Á¶±â ¹ß°ßÀ» À§Çؼ­´Â ºÐÀÚ °Ë»ç°¡ ÇʼöÀûÀÔ´Ï´Ù. 2017³â ÀÌÈÄ È£ÁÖ, ³×´ú¶õµå µîÀÇ ±¹°¡¿¡¼­´Â ¹Î°¨µµ°¡ ³ô°í °ËÁø °£°ÝÀÌ ±æ´Ù´Â ÀÌÀ¯·Î ÀڱðæºÎ¾Ï °Ë»ç¿¡¼­ 1Â÷ HPV DNA °Ë»ç·Î ÀüȯÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå : ±â¼ú ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦9Àå °æÀï ±¸µµ

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Human Papilloma Virus Testing Market Summary

The human papilloma virus testing market size was estimated at USD 1.76 billion in 2024 and is projected to reach USD 5.67 billion by 2033, growing at a CAGR of 14.14% from 2025 to 2033. The market is fueled by rising HPV-related cancer cases, with human papilloma virus (HPV) causing over 95% of cervical cancers.

Countries like Australia have replaced Pap smears with HPV DNA testing for higher sensitivity. Self-sampling kits, such as those from BD and Hologic, are expanding access in underserved areas. WHO's elimination strategy and NGO-backed programs in Africa and Asia drive adoption. Advances in molecular diagnostics, bundled women's health panels, and improved lab infrastructure make testing more accessible and cost-effective globally. Cervical cancer is the fourth most common cancer among women worldwide and the second leading cause of female cancer-related mortality.

In November 2020, the World Health Organization launched its Global Strategy to Eliminate Cervical Cancer, setting the 90-70-90 targets for 2030-vaccinate 90% of girls by age 15, screen 70% of women at ages 35 and 45, and treat 90% of women with identified disease. This initiative came against alarming statistics: in 2022, only 18% of countries had reached the recommended screening coverage of over 70%, and global coverage still stood at about 20%. HPV is the causative agent in 99.8% of cervical cancer cases, with genotypes 16 and 18 alone responsible for 70% of cases. Nineteen high-risk genotypes account for 90% of all HPV-related cancers. Given the asymptomatic nature of most HPV infections, molecular testing has become essential for early detection. Since 2017, countries such as Australia and the Netherlands have transitioned from Pap smears to primary HPV DNA testing, citing higher sensitivity and longer screening intervals.

Global Human Papilloma Virus Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global human papilloma virus (HPV) testing market report based on application, product, technology, end use, and region:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Human Papilloma Virus (HPV) Testing Market Variables, Trends, & Scope

Chapter 4. Human Papilloma Virus (HPV) Testing Market: Application Estimates & Trend Analysis

Chapter 5. Human Papilloma Virus (HPV) Testing Market: Product Estimates & Trend Analysis

Chapter 6. Human Papilloma Virus (HPV) Testing Market: Technology Estimates & Trend Analysis

Chapter 7. Human Papilloma Virus (HPV) Testing Market: End Use Estimates & Trend Analysis

Chapter 8. Human Papilloma Virus (HPV) Testing Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â